ReCode Therapeutics: Funding, Investors & Team (Sep 2026)
ReCode Therapeutics is an improvement stage biopharmaceutical organization zeroed in on the remedy of the rubbish changes that record for 1/3 of generally acquired illnesses, including roughly 10% of cystic fibrosis. They have joined chosen tRNAs with their special and various restrictive conveyance stages to make and foster first-in-class silencer tRNA-nanoparticle therapeutics for amending rubbish changes. ReCode's assorted pipeline incorporates lead programs for essential ciliary dyskinesia (PCD) and rubbish transformations in cystic fibrosis (CF). The organization's restrictive non-viral lipid nanoparticle stage empowers the conveyance of different payloads, and exact organ focusing of nucleic corrosive and protein payloads by means of both fundamental and neighborhood conveyance. ReCode is utilizing its nanoparticle and nucleic corrosive advancements across different modalities, including mRNA-intervened protein substitution treatments, first-in-class tRNA NanoCorrectors for illnesses brought about by hogwash transformations, and quality altering. The organization was established in 2015 and is situated in Dallas, Texas.
ReCode Therapeutics has raised $195M across 4 funding rounds on record, the most recent an undisclosed round of $15.0M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ReCode Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2024.
ReCode Therapeutics Funding Rounds
ReCode Therapeutics raised $120M in a Series B announced in Jun 2022.
7 months later, an undisclosed round of $10.0M was announced in Jan 2023.
8 months later, a Series B of $50.0M was announced in Sep 2023.
1.2 years later, an undisclosed round of $15.0M was announced in Nov 2024.
ReCode Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
ReCode Therapeutics Funding Compared to Other Biotechnology Startups
ReCode Therapeutics' latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ReCode Therapeutics in Biotechnology and Dallas
Companies Similar to ReCode Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
ReCode Therapeutics Funding FAQs
What does ReCode Therapeutics do?
ReCode Therapeutics is an improvement stage biopharmaceutical organization zeroed in on the remedy of the rubbish changes that record for 1/3 of generally acquired illnesses, including roughly 10% of cystic fibrosis. They have joined chosen tRNAs with their special and various restrictive conveyance stages to make and foster first-in-class silencer tRNA-nanoparticle therapeutics for amending rubbish changes. ReCode's assorted pipeline incorporates lead programs for essential ciliary dyskinesia (PCD) and rubbish transformations in cystic fibrosis (CF). The organization's restrictive non-viral lipid nanoparticle stage empowers the conveyance of different payloads, and exact organ focusing of nucleic corrosive and protein payloads by means of both fundamental and neighborhood conveyance. ReCode is utilizing its nanoparticle and nucleic corrosive advancements across different modalities, including mRNA-intervened protein substitution treatments, first-in-class tRNA NanoCorrectors for illnesses brought about by hogwash transformations, and quality altering. The organization was established in 2015 and is situated in Dallas, Texas.
How much funding has ReCode Therapeutics raised?
ReCode Therapeutics has raised $195M across 4 rounds on record. The most recent is an undisclosed round of $15.0M announced in Nov 2024.
When did ReCode Therapeutics last raise funding?
ReCode Therapeutics' most recent funding round on record is an undisclosed round of $15.0M, announced in Nov 2024.
Who founded ReCode Therapeutics?
FundedIQ lists Daniel Siegwart (Founder), Philip Thomas (Founder) at ReCode Therapeutics.
Where is ReCode Therapeutics headquartered?
ReCode Therapeutics is based in Dallas, Texas, United States.
How many employees does ReCode Therapeutics have?
ReCode Therapeutics is in the 51-100 employee band.
How does ReCode Therapeutics' funding compare to other Biotechnology startups?
ReCode Therapeutics' latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's ReCode Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ReCode Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.